Select Publications
Book Chapters
2022, 'Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy: A Recent Study', in Current Innovations in Medicine and Medical Science Vol. 3, Book Publisher International (a part of SCIENCEDOMAIN International), pp. 61 - 87, http://dx.doi.org/10.9734/bpi/cimms/v3/7736f
,2021, 'Cell-based methods for the identification of Myc-inhibitory small molecules', in The Myc Gene: Methods and Protocols, pp. 337 - 346, http://dx.doi.org/10.1007/978-1-0716-1476-1_19
,2014, 'Clinical relevance of multidrug-resistance-proteins (MRPs) for anticancer drug resistance and prognosis', in Efferth T; Bonavida B (ed.), Resistancce to Targeted Anti-Cancer Therapeutics, Springer Press., pp. 27 - 52
,2013, 'Cell-Based Methods for the Identification of MYC-Inhibitory Small Molecules', in Soucek L; Sodir NM (ed.), The Myc Gene, Humana Press Inc, pp. 255 - 264, http://dx.doi.org/10.1007/978-1-62703-429-6_18
,2013, 'Oncogene and Cancer - From Bench to Clinic', in Siregar YE; norris (ed.), Oncogene and Cancer - From Bench to Clinic, Inst za onkologiju i radiol, pp. 437 - 454, http://dx.doi.org/10.5772/54813
,2012, 'Small molecule drugs and targeted therapies for neuroblastoma', in Shimada H (ed.), Neuroblastoma - Present and Future, In Tech, Croatia, pp. 299 - 324, http://www.amazon.com/Neuroblastoma-Present-and-Future-ebook/dp/B00CBWQI92/ref=sr_1_1?ie=UTF8&qid=1366940364&sr=8-1&keywords=neuroblastoma+-+present+and+future#reader_B00CBWQI92
,2012, 'Targeting Multidrug Resistance in Neuroblastoma', in Hayat MA (ed.), Pediatric Cancer Volume 1 Diagnosis, Therapy and Prognosis: Neuroblastoma, Springer, New York, USA, pp. 115 - 123, http://dx.doi.org/10.1007/978-94-007-2418-1_11
,2012, 'The Myc Gene: Methods and Protocols: Myc inhibitory molecules', in Methods in Molecular Biology, Humana Press
,2000, 'Multidrug Resistance Genes in Neuroblastoma', in Neuroblastoma, Elsevier Science BV, Amsterdam, pp. 207 - 215
,Journal articles
2024, 'Golgi-localized Ring Finger Protein 121 is necessary for MYCN-driven neuroblastoma tumorigenesis', Communications Biology, 7, http://dx.doi.org/10.1038/s42003-024-06899-8
,2024, 'The Eyes Absent family members EYA4 and EYA1 promote PLK1 activation and successful mitosis through tyrosine dephosphorylation', Nature Communications, 15, http://dx.doi.org/10.1038/s41467-024-45683-4
,2024, 'The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis', Nature Communications, 15, http://dx.doi.org/10.1038/s41467-024-49871-0
,2024, 'Abstract A044 Enhanced disease detection using single cell RNAseq in children with brain cancer', Cancer Research, 84, pp. A044 - A044, http://dx.doi.org/10.1158/1538-7445.pediatric24-a044
,2024, 'Abstract B007: High-risk pediatric cancer models in zebrafish, mouse and short-term culture predict individual patient responses to therapy', Cancer Research, 84, pp. B007 - B007, http://dx.doi.org/10.1158/1538-7445.pediatric24-b007
,2024, 'Abstract B012: Clinical utility of real-time comprehensive molecular profiling in childhood brain tumors', Cancer Research, 84, pp. B012 - B012, http://dx.doi.org/10.1158/1538-7445.pediatric24-b012
,2024, 'Abstract B014: Increasing the clinical utility of transcriptome analysis in high-risk childhood precision oncology', Cancer Research, 84, pp. B014 - B014, http://dx.doi.org/10.1158/1538-7445.pediatric24-b014
,2024, 'Loss of the stress sensor GADD45A promotes stem cell activity and ferroptosis resistance in LGR4/HOXA9-dependent AML', Blood, 144, pp. 84 - 98, http://dx.doi.org/10.1182/blood.2024024072
,2024, 'Precision-guided treatment in high-risk pediatric cancers', Nature Medicine, 30, pp. 1913 - 1922, http://dx.doi.org/10.1038/s41591-024-03044-0
,2024, 'FDA-approved disulfiram as a novel treatment for aggressive leukemia', Journal of Molecular Medicine, 102, pp. 507 - 519, http://dx.doi.org/10.1007/s00109-023-02414-4
,2024, 'Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial', British Journal of Cancer, 130, pp. 788 - 797, http://dx.doi.org/10.1038/s41416-023-02525-2
,2024, 'Abstract 2673: Copper chelation overcomes the immunosuppressive neuroblastoma microenvironment to potentiate anti-GD2 antibody therapy', Cancer Research, 84, pp. 2673 - 2673, http://dx.doi.org/10.1158/1538-7445.am2024-2673
,2024, 'Single-base tiled screen unveils design principles of PspCas13b for potent and off-target-free RNA silencing', Nature Structural and Molecular Biology, http://dx.doi.org/10.1038/s41594-024-01336-0
,2024, '438 (PB426): Precision-guided treatment improves outcomes for children with highrisk cancers', European Journal of Cancer, 211, pp. 114946 - 114946, http://dx.doi.org/10.1016/j.ejca.2024.114946
,2023, 'A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer', Genome Medicine, 15, http://dx.doi.org/10.1186/s13073-023-01170-x
,2023, 'Abstract B132: Addition of AMXT1501 (polyamine uptake inhibitor) plus DFMO (polyamine synthesis inhibitor) to standard-of-care chemotherapy/anti-GD2 antibody in the TH-MYCN mouse neuroblastoma model, enhances efficacy compared to addition of DFMO alone', Molecular Cancer Therapeutics, 22, pp. B132 - B132, http://dx.doi.org/10.1158/1535-7163.targ-23-b132
,2023, 'Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes', Scientific Reports, 13, pp. 3775, http://dx.doi.org/10.1038/s41598-023-30395-4
,2023, 'Hopes, concerns, satisfaction and regret in a precision medicine trial for childhood cancer: a mixed-methods study of parent and patient perspectives', British Journal of Cancer, 129, pp. 1634 - 1644, http://dx.doi.org/10.1038/s41416-023-02429-1
,2023, 'Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma', International Journal of Molecular Sciences, 24, http://dx.doi.org/10.3390/ijms242115571
,2023, 'High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer', Cancer Research, 83, pp. 2716 - 2732, http://dx.doi.org/10.1158/0008-5472.CAN-22-3702
,2023, 'Precision Medicine Is Changing the Roles of Healthcare Professionals, Scientists, and Research Staff: Learnings from a Childhood Cancer Precision Medicine Trial', Journal of Personalized Medicine, 13, http://dx.doi.org/10.3390/jpm13071033
,2023, 'Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia', Science translational medicine, 15, pp. eabm1262 - eabm1262, http://dx.doi.org/10.1126/scitranslmed.abm1262
,2023, 'Memory of stochastic single-cell apoptotic signaling promotes chemoresistance in neuroblastoma', Science Advances, 9, http://dx.doi.org/10.1126/sciadv.abp8314
,2023, 'Heritable defects in telomere and mitotic function selectively predispose to sarcomas', Science, 379, pp. 253 - 260, http://dx.doi.org/10.1126/science.abj4784
,2022, 'Inflammatory response to retrotransposons drives tumor drug resistance that can be prevented by reverse transcriptase inhibitors', Proceedings of the National Academy of Sciences of the United States of America, 119, http://dx.doi.org/10.1073/pnas.2213146119
,2022, 'Donor T cells for CAR T cell therapy', Biomarker Research, 10, pp. 14, http://dx.doi.org/10.1186/s40364-022-00359-3
,2022, 'GSH facilitates the binding and inhibitory activity of novel multidrug resistance protein 1 (MRP1) modulators', FEBS Journal, 289, pp. 3854 - 3875, http://dx.doi.org/10.1111/febs.16374
,2022, 'The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression', Frontiers in Oncology, 12, pp. 863329, http://dx.doi.org/10.3389/fonc.2022.863329
,2022, 'In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer', EMBO Molecular Medicine, 14, pp. emmm202114608, http://dx.doi.org/10.15252/emmm.202114608
,2022, 'Suppression of the ABCA1 Cholesterol Transporter Impairs the Growth and Migration of Epithelial Ovarian Cancer', Cancers, 14, pp. 1878, http://dx.doi.org/10.3390/cancers14081878
,2022, 'Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia', Frontiers in Oncology, 11, pp. 779859, http://dx.doi.org/10.3389/fonc.2021.779859
,2022, 'Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma', International Journal of Cancer, 152, pp. 1399 - 1413, http://dx.doi.org/10.1002/ijc.34349
,2022, 'Methodological advances in the discovery of novel neuroblastoma therapeutics', Expert Opinion on Drug Discovery, 17, pp. 167 - 179, http://dx.doi.org/10.1080/17460441.2022.2002297
,2021, 'Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas', Nature Communications, 12, pp. 971, http://dx.doi.org/10.1038/s41467-021-20896-z
,2021, 'Enhancing the potential of immunotherapy in paediatric sarcomas: Breaking the immunosuppressive barrier with receptor tyrosine kinase inhibitors', Biomedicines, 9, pp. 1798, http://dx.doi.org/10.3390/biomedicines9121798
,2021, 'Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition', Drug Resistance Updates, 59, pp. 100795, http://dx.doi.org/10.1016/j.drup.2021.100795
,2021, 'A Primer for Assessing the Pathology in Mouse Models of Neuroblastoma', Current Protocols, 1, pp. e310, http://dx.doi.org/10.1002/cpz1.310
,2021, 'Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia', Leukemia, 35, pp. 3101 - 3112, http://dx.doi.org/10.1038/s41375-021-01248-8
,2021, 'Early-phenotype CAR-T cells for the treatment of pediatric cancers', Annals of Oncology, 32, pp. 1366 - 1380, http://dx.doi.org/10.1016/j.annonc.2021.07.018
,2021, 'Chimeric antigen receptor t cell therapy and the immunosuppressive tumor microenvironment in pediatric sarcoma', Cancers, 13, pp. 4704, http://dx.doi.org/10.3390/cancers13184704
,2021, 'Dual targeting of chromatin stability by the curaxin CBL0137 and histone deacetylase inhibitor panobinostat shows significant preclinical efficacy in neuroblastoma', Clinical Cancer Research, 27, pp. 4338 - 4352, http://dx.doi.org/10.1158/1078-0432.CCR-20-2357
,